Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (88)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (217)
  2. Department of Medicine (217)
  3. Solid Tumor Oncology Division (217)
  4. GSK Faculty (58)
  5. Survivorship Research (45)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (23)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (10)
  5. European Journal of Cancer (5)
  6. New England Journal of Medicine (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (47)
  3. Oxford University Press (23)
  4. Elsevier Inc. (16)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (217)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Primäre ergebnisse der TROPiCS-02: Eine randomisierte phase 3 studie mit sacituzumab govitecan vs. behandlung nach wahl des arztes (TPC) bei patienten mit hormonrezeptor-positivem/HER2-negativem (HR+/HER2-) fortgeschrittenem mammakarzinom
    Meeting Abstract

    Marmé, F.; Rugo, H. S.; Bardia, A.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Gómez Pardo, P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Shen, S.; Salehi, E.; Farooki, A.; Flory, J.; Williams, D.; Carpio, A.; Chang, C.; Lacouture, M. E.; Andreopoulou, E.; Sardesai, S. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC)
    Meeting Abstract

    Rugo, H. S.; O'Shaughnessy, J.; Jhaveri, K. L.; Tolaney, S. M.; Cardoso, F.; Bardia, A.; Maheshwari, V. K.; Tripathi, S.; Pathak, P.; Haftchenary, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER
    Meeting Abstract

    Jhaveri, K. L.; Jeselsohn, R.; Lim, E.; Hamilton, E. P.; Yonemori, K.; Beck, J. T.; Kaufman, P. A.; Sammons, S.; Bhave, M. A.; Saura, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial
    Meeting Abstract

    Jhaveri, K. L.; Goldman, J. W.; Hurvitz, S. A.; Guerrero-Zotano, A.; Unni, N.; Brufsky, A.; Park, H.; Waisman, J. R.; Yang, E. S. H.; Spanggaard, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC)
    Meeting Abstract

    Bedard, P. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Juric, D.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC)
    Meeting Abstract

    Andre, F.; Hamilton, E. P.; Loi, S.; Im, S. A.; Sohn, J.; Tseng, L. M.; Anders, C. K.; Schmid, P.; Boston, S.; Darilay, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: Findings from the SUMMIT basket trial
    Meeting Abstract

    Goldman, J.; Bueno, A. M.; Dooms, C.; Jhaveri, K.; de Miguel, M. J.; Piha-Paul, S. A.; Unni, N.; Mahipal, A.; Suga, J. M.; Naltet, C.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2
    Meeting Abstract

    Jhaveri, K.; O'Shaughnessy, J.; Fasching, P.; Cardoso, F.; Tolaney, S.; Hamilton, E.; Sharma, V. K.; Biswas, C.; Haftchenary, S.; Pathak, P.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save